DuoPlavin

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
07-07-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
07-07-2023

Viambatanisho vya kazi:

clopidogrel, Acetylsalicylic acid

Inapatikana kutoka:

Sanofi Winthrop Industrie

ATC kanuni:

B01AC30

INN (Jina la Kimataifa):

clopidogrel, acetylsalicylic acid

Kundi la matibabu:

Antithrombotic agents

Eneo la matibabu:

Acute Coronary Syndrome; Myocardial Infarction

Matibabu dalili:

DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in:Non ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (PCI);ST segment elevation acute myocardial infarction (STEMI) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.For further information please refer to section 5.1.

Bidhaa muhtasari:

Revision: 30

Idhini hali ya:

Authorised

Idhini ya tarehe:

2010-03-14

Taarifa za kipeperushi

                                41
B. PACKAGE LEAFLET
42
PACKAGE LEAFLET: INFORMATION FOR THE USER
DUOPLAVIN 75 MG/75 MG FILM-COATED TABLETS
DUOPLAVIN 75 MG/100 MG FILM-COATED TABLETS
clopidogrel/acetylsalicylic acid
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What DuoPlavin is and what it is used for
2.
What you need to know before you take DuoPlavin
3.
How to take DuoPlavin
4.
Possible side effects
5
How to store DuoPlavin
6.
Contents of the pack and other information
1.
WHAT DUOPLAVIN IS AND WHAT IT IS USED FOR
DuoPlavin contains clopidogrel and acetylsalicylic acid (ASA) and
belongs to a group of medicines
called antiplatelet medicinal products. Platelets are very small
structures in the blood which clump
together during blood clotting. By preventing this clumping in some
types of blood vessels (called
arteries), antiplatelet medicinal products reduce the chances of blood
clots forming (a process called
atherothrombosis).
DuoPlavin is taken by adults to prevent blood clots forming in
hardened arteries which can lead to
atherothrombotic events (such as stroke, heart attack, or death).
You have been prescribed DuoPlavin in place of the two separate
medicines, clopidogrel and ASA, to
help prevent blood clots because you have experienced a severe type of
chest pain known as ‘unstable
angina’ or heart attack (myocardial infarction). For the treatment
of this condition your doctor may
have placed a stent in the blocked or narrowed artery to restore
effective blood flow.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DUOPLAV
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
DuoPlavin 75 mg/75 mg film-coated tablets
DuoPlavin 75 mg/100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
DuoPlavin 75 mg/75 mg film-coated tablets
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 75 mg of
acetylsalicylic acid (ASA).
_Excipients with known effect: _
Each film-coated tablet contains 7 mg of lactose and 3.3 mg of
hydrogenated castor oil.
DuoPlavin 75 mg/100 mg film-coated tablets
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 100 mg of
acetylsalicylic acid (ASA).
_Excipients with known effect: _
Each film-coated tablet contains 8 mg of lactose and 3.3 mg of
hydrogenated castor oil.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
DuoPlavin 75 mg/75 mg film-coated tablets
Yellow, oval, slightly biconvex, engraved with «C75» on one side and
«A75» on the other side.
DuoPlavin 75 mg/100 mg film-coated tablets
Light pink, oval, slightly biconvex, engraved with «C75» on one side
and «A100» on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
DuoPlavin is indicated for the secondary prevention of
atherothrombotic events in adult patients
already taking both clopidogrel and acetylsalicylic acid (ASA).
DuoPlavin is a fixed-dose combination
medicinal product for continuation of therapy in:
•
Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave
myocardial infarction) including patients undergoing a stent placement
following percutaneous
coronary intervention (PCI)
•
ST segment elevation acute myocardial infarction (STEMI) in patients
undergoing PCI
(including patients undergoing a stent placement) or medically treated
patients eligible for
thrombolytic/ fibrinolytic therapy
For further information please refer to section 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and elderly _
DuoPlavin 75 mg/75 mg film-coated ta
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kireno 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 16-02-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 07-07-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 07-07-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 07-07-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 07-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 16-02-2023

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati